These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 33274176)

  • 1. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
    Harrell CR; Jovicic BP; Djonov V; Volarevic V
    Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome.
    Tovar I; Guerrero R; López-Peñalver JJ; Expósito J; Ruiz de Almodóvar JM
    Cells; 2020 Sep; 9(9):. PubMed ID: 32887260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
    Kaye RJ
    Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
    Qin H; Zhao A
    Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
    Khoury M; Cuenca J; Cruz FF; Figueroa FE; Rocco PRM; Weiss DJ
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32265310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
    Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
    Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
    Gu J; Zhao Q; Han Z; Han Z
    Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.
    Laroye C; Gibot S; Huselstein C; Bensoussan D
    Stem Cells Transl Med; 2020 Dec; 9(12):1488-1494. PubMed ID: 32808462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review.
    Montenegro F; Unigarro L; Paredes G; Moya T; Romero A; Torres L; López JC; González FEJ; Del Pozo G; López-Cortés A; Diaz AM; Vasconez E; Cevallos-Robalino D; Lister A; Ortiz-Prado E
    Expert Rev Respir Med; 2021 Feb; 15(2):183-195. PubMed ID: 32902367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
    Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP
    Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Placental Mesenchymal Stromal Cell Secretome from Two- and Three-Dimensional Cell Cultures Promotes Survival and Regeneration in Acute Lung Injury Model in Mice.
    Kudinov VA; Artyushev RI; Zurina IM; Zorina ES; Lapshin RD; Snopova LB; Mukhina IV; Saburina IN
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.
    Wang XY
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4537-4538. PubMed ID: 32373992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
    Xiong J; Bao L; Qi H; Feng Z; Shi Y
    Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
    Al-Khawaga S; Abdelalim EM
    Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential.
    Khoury M; Rocco PRM; Phinney DG; Krampera M; Martin I; Viswanathan S; Nolta JA; LeBlanc K; Galipeau J; Weiss DJ
    Cytotherapy; 2020 Nov; 22(11):602-605. PubMed ID: 32933835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
    Yen BL; Yen ML; Wang LT; Liu KJ; Sytwu HK
    Stem Cells Transl Med; 2020 Oct; 9(10):1163-1173. PubMed ID: 32526079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.